Motuporin

Summary

Motuporin is a cyclic pentapeptide originally isolated from cyanobacteria and marine sponges. It acts as a potent inhibitor of protein phosphatases PP1 and PP2A, enzymes that remove phosphate groups from serine/threonine residues. The compound is used experimentally to probe phosphatase function and as a scaffold for designing selective inhibitors. Because the inhibition is rapid and reversible, motuporin serves as a valuable chemical probe for dissecting signaling pathways that depend on PP1/PP2A activity.

Mechanism of Action

Motuporin binds directly to the catalytic subunits of protein phosphatase‑1 (PP1c) and protein phosphatase‑2A (PP2Ac), causing rapid loss of enzymatic activity. Unlike the related heptapeptide microcystins, motuporin does not form a covalent Michael‑addition adduct with the phosphatase; inhibition is achieved through a non‑covalent interaction that remains stable for hours. Structural studies indicate that the N‑methyldehydrobutyrine residue of motuporin is positioned such that it does not react with nucleophilic residues in the enzyme, yet the peptide still occupies the active site and blocks substrate access.

What the Research Shows

Early biochemical work showed that motuporin rapidly inactivates PP1c and PP2Ac without forming covalent adducts, in contrast to microcystins. Total syntheses of the natural product and several analogues have been reported, confirming that the N‑methyldehydrobutyrine residue is not essential for inhibition, as alanine‑substituted analogues retain comparable IC50 values in rat adipocyte lysates. Simplified analogues containing only the Adda moiety and one additional amino acid display mid‑nanomolar inhibition of PP1/PP2A, highlighting the core pharmacophore. Natural product surveys of Theonella swinhoei sponges revealed multiple diastereomeric motuporin variants, expanding the structural landscape. To date, investigations have been limited to in vitro enzyme assays and chemical synthesis, with no animal disease models reported.

Reported Benefits

Motuporin provides a highly specific tool for studying PP1 and PP2A biology, allowing researchers to acutely block phosphatase activity and observe downstream signaling effects. Its rapid, reversible inhibition makes it suitable for time‑resolved experiments. The peptide also serves as a scaffold for developing more selective or drug‑like phosphatase inhibitors, as evidenced by analogues that retain activity with simplified structures.

Limitations of the Evidence

Evidence for motuporin is confined to biochemical assays and synthetic chemistry studies; no in vivo efficacy or pharmacokinetic data have been reported. Selectivity beyond PP1/PP2A has not been comprehensively evaluated, raising the possibility of off‑target effects. The compound is a known hepatotoxin, limiting its translational potential without substantial modification. Synthesis of the natural stereochemistry is complex, which may hinder large‑scale exploration.

Safety Considerations

Motuporin is classified as a hepatotoxin because it potently inhibits essential serine/threonine phosphatases that regulate cellular metabolism. Inhibition of PP1/PP2A can lead to widespread dysregulation of signaling pathways and cell death. No human safety data exist, and the compound should be handled with standard laboratory protective measures, avoiding exposure to skin, eyes, or inhalation. Toxicity assessments have been limited to cell lysates, indicating cytotoxic potential at low nanomolar concentrations.

How It Is Administered

In research settings motuporin has been delivered by injection routes, typically intravenous or subcutaneous, to achieve systemic exposure in animal or ex vivo studies. The peptide is administered as a sterile solution; no commercial formulation exists. Dosing regimens are experimental and vary according to the specific assay or model used.

Routes of Administration

Goals & Uses

• ImmunosuppressionTherapeuticModerate

Contraindications

No contraindications recorded yet.

Adverse Effects

No adverse effects recorded yet.

Drug Interactions

No drug interactions recorded yet.

Population Constraints

No population constraints recorded yet.

Regulatory Status

• United StatesUnapprovedInvestigational peptide, no regulatory approval

Evidence & Sources

• Molecular mechanisms underlying he interaction of motuporin and microcystins with type-1 and type-2A protein phosphatases
  Journal ArticleLowCraig M, et al.1996-01-01T00:00:00.000000Z
• Total Synthesis of Motuporin and 5-[L-Ala]-Motuporin
  Journal ArticleLowSamy R, et al.1999-01-01T00:00:00.000000Z
• Microcystin analogues comprised only of Adda and a single additional amino acid retain moderate activity as PP1/PP2A inhibitors
  Journal ArticleLowGulledge BM, et al.2003-01-01T00:00:00.000000Z
• Total Synthesis of (-)-Motuporin
  Journal ArticleLowHu T, Panek JS1999-01-01T00:00:00.000000Z
• A serendipitous discovery of isomotuporin-containing sponge populations of Theonella swinhoei
  Journal ArticleLowWegerski CJ, et al.2007-01-01T00:00:00.000000Z
• Enantioselective synthesis of the protein phosphatase inhibitor (-)-motuporin
  Journal ArticleLowHu T, Panek JS2002-01-01T00:00:00.000000Z

Frequently Asked Questions